Karyopharm Therapeutics Inc. filed Chapter 11 on November 2, 2026, cannot file its Form 10-Q, and Nasdaq suspended trading on November 11, 2026. Its plan cancels equity without distribution, with Ayrmid transaction expected to close in first quarter of 2027.
KPTI · Karyopharm Therapeutics Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Based on our current business plan and current capital resources, combined with the uncertainty regarding the availability of additional funding or other strategic alternatives and considering our debt service obligations and financial covenant to maintain minimum liquidity, we have concluded that there is substantial doubt regarding our ability to continue as a going concern within one year after the date the accompanying condensed consolidated financial statements are issued.”View the 10-Q filed Aug 13, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
After Karyopharm Therapeutics Inc. filed Chapter 11 petitions on November 2, 2026, Nasdaq notified it that securities will be delisted. Trading will suspend November 11, 2026; it will not appeal and expects existing equity securities to have no value.
Karyopharm Therapeutics Inc. and KPT Texas LLC filed Chapter 11 on November 2, 2026, seeking a $110 million DIP facility and an Ayrmid-led restructuring that would cancel existing equity.
Karyopharm Therapeutics Inc. plans a merger with Ayrmid Ltd. and filed Chapter 11 petitions. The deal is expected to close in the first quarter of 2027 with up to $55 million in DIP financing; equity is expected to have no value.
Karyopharm Therapeutics Inc. further extended the end of its forbearance period from 11:59 p.m., Eastern time, on October 22, 2026 to 11:59 p.m., Eastern time, on November 1, 2026, absent earlier termination.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Aug 13, 2026TL;DR. Karyopharm remains on track to submit its sNDA in August seeking accelerated approval of selinexor plus ruxolitinib in myelofibrosis, while reaffirming its 2026 revenue guidance; however, the XPORT-EC-042 Phase 3 in endometrial cancer failed to meet its primary endpoint, and the company warned that without additional financing or a lender waiver, a $15.8 million September 10 payment would push liquidity below its $10 million covenant and trigger a default.
- + Company remains on track to submit sNDA in August for selinexor plus ruxolitinib in myelofibrosis under accelerated approval, with FDA written feedback that SVR35 appears to qualify as a reasonably likely surrogate endpoint.
- + SVR35 responses with the selinexor plus ruxolitinib combination were nearly double those of ruxolitinib alone at week 24 and were rapid, deep, and sustained through week 36.
- + Phase 3 SENTRY overall survival hazard ratio was 0.43 and SVR35 was shown to predict overall survival, supporting the regulatory package.
- + U.S. XPOVIO net product revenue rose to $30.8 million in Q2 2026 from $29.7 million in Q2 2025, and R&D and SG&A expenses declined year over year.
- − Cash runway only extends into September 2026, and a $15.8 million term loan payment due September 10, 2026 without additional financing or a lender waiver would push liquidity below the $10 million minimum covenant and trigger an event of default.
- − Q2 2026 net loss widened to $67.0 million from $37.3 million in the prior-year period, driven primarily by $32.1 million of non-cash other expense from mark-to-market adjustments.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Total license and other revenue | 2.66M | the three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
KPTI
this stock
Karyopharm Therapeutics Inc.
|
$408,266 | -99.8% | +0.6% | — | 36.3% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$132.01B | +14.8% | +46.2% | 33.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.52B | +19.6% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$80.65B | +575.9% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.15B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 13, 2026
- This year
- 31
Karyopharm Therapeutics Inc. filed Chapter 11 on November 2, 2026, cannot file its Form 10-Q, and Nasdaq suspended trading on November 11, 2026. Its plan cancels equity without distribution, with Ayrmid transaction expected to close in first quarter of 2027.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| KPTI | -75.3% | -94.3% | -99.8% | -97.3% | -99.8% |
| SPY | -0.9% | -1.3% | +2.3% | +0.5% | +11.4% |
| vs SPY | -74.4% | -93.0% | -102.1% | -97.8% | -111.2% |